Evidence map›Paper›PMID 31126047›Full record

ReviewSensors (Basel, Switzerland)2019

The Advent of Salivary Breast Cancer Biomarker Detection Using Affinity Sensors.

Imad Abrao Nemeir, Joseph Saab, Walid Hleihel, Abdelhamid Errachid, Nicole Jafferzic-Renault, Nadia Zine

Open access · goldAbstract readReview
In one paragraph

Review in Sensors (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Molecular Diagnosis and Cancer Prognosis-A Concise Review.Diagnostics (Basel, Switzerland) · 2023
    Review
  4. Review
  5. Proteomics and its applications in breast cancer.American journal of cancer research · 2021
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Imad Abrao NemeirFaculty of Sciences, Holy Spirit University of Kaslik, 446 Jounieh, Mount Lebanon, Lebanon. imad.abraonemeir@isa-lyon.fr.
Joseph SaabFaculty of Sciences, Holy Spirit University of Kaslik, 446 Jounieh, Mount Lebanon, Lebanon. josephsaab@usek.edu.lb.
Walid HleihelFaculty of Sciences, Holy Spirit University of Kaslik, 446 Jounieh, Mount Lebanon, Lebanon. walidhleihel@usek.edu.lb.
Abdelhamid ErrachidInstitut des Sciences Analytiques, Université de Lyon, Claude Bernard Lyon 1, UMR 5280, CNRS - 5, rue de la Doua, 69100 Villeurbanne, France. abdelhamid.errachid-el-salhi@univ-lyon1.fr.
Nicole Jafferzic-RenaultInstitut des Sciences Analytiques, Université de Lyon, Claude Bernard Lyon 1, UMR 5280, CNRS - 5, rue de la Doua, 69100 Villeurbanne, France. nicole.jaffrezic@univ-lyon1.fr.ORCID 0000-0003-1354-9273
Nadia ZineInstitut des Sciences Analytiques, Université de Lyon, Claude Bernard Lyon 1, UMR 5280, CNRS - 5, rue de la Doua, 69100 Villeurbanne, France. imad-nmeir@hotmail.com.
Université Claude Bernard Lyon 1 · FRHoly Spirit University of Kaslik · LBLebanese University · LB

Funding

Horizon 2020 Framework Programme 768686UK-Lebanon Tech Hub Primispot
6 · The paper itself

Abstract

Breast Cancer is one of the world's most notorious diseases affecting two million women in 2018 worldwide. It is a highly heterogeneous disease, making it difficult to treat. However, its linear progression makes it a candidate for early screening programs, and the earlier its detection the higher the chance of recovery. However, one key hurdle for breast cancer screening is the fact that most screening techniques are expensive, time-consuming, and cumbersome, making them impractical for use in several parts of the world. One current trend in breast cancer detection has pointed to a possible solution, the use of salivary breast cancer biomarkers. Saliva is an attractive medium for diagnosis because it is readily available in large quantities, easy to obtain at low cost, and contains all the biomarkers present in blood, albeit in lower quantities. Affinity sensors are devices that detect molecules through their interactions with biological recognition molecules. Their low cost, high sensitivity, and selectivity, as well as rapid detection time make them an attractive alternative to traditional means of detection. In this review article, we discuss the current status of breast cancer diagnosis, its salivary biomarkers, as well as the current trends in the development of affinity sensors for their detection.

Indexed as

AutoantibodiesBiomarkers, TumorBreast NeoplasmsFemaleHumansMammographyMetabolomicsMicroRNAsMucinsSalivaAutoantibodiesBiomarkers, TumorMicroRNAsMucinsaffinity biosensors (AS)Breast Cancer (BC)Diagnosisenzyme-linked immunosorbent assay (ELISA)

Identifiers

PMID31126047
PMCPMC6566681
OpenAlexW2946267826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.